OFIX
Orthofix MedicalFDocument history
Earnings documents stored for OFIX.
Investor releaseQuarter not tagged2026-05-06Orthofix Medical Inc. Q1 2026 Earnings Call Summary
Moby
Orthofix Medical Inc. Q1 2026 Earnings Call Summary
Performance was driven by the successful completion of distributor transitions, with the top 30 partners delivering 27% year-over-year growth. Management simplified the spine leadership structure in April to bring decision-making closer to the field and increase accountability as the company scales. Spine Fixation growth of 6% was supported by deeper procedural penetration and the 7D FLASH navigation system acting as a core differentiator for surgeon engagement. Biologics performance improved sequentially following targeted actions to expand account penetration and increase utilization across both spine and orthopedic portfolios. The company is shifting focus from restructuring to execution, prioritizing high-value categories and deemphasizing lower-return products in the Limb Reconstruction segment. Therapeutic Solutions continues to outperform the market, serving as a reliable contributor to overall margin expansion and cash generation. Full-year guidance assumes a growth acceleration from 5% in the first half to 6% in the second half of 2026. The second half of the year is expected to benefit from the full market launch of the VIRATA open system and the alpha launch of VIRATA MIS. Limb Reconstruction is projected to return to double-digit growth in the U.S. during the second half of 2026 as capital sales pipelines strengthen. Management expects to exit 2026 with a more durable growth profile in Biologics by building clinical evidence and supporting physician advocacy. Free cash flow is projected to be positive for the full year, excluding potential legal settlements, supported by disciplined capital deployment. The CMS TEAM pilot program had a one-time impact of less than 0.5% on the fourth quarter growth rate, which was lower than the originally anticipated 1% impact. First quarter growth was negatively impacted by approximately 1.6% due to having one less selling day compared to the prior year. International results were boosted by approximately $2 million in timing-related stocking orders, which offset some softness in the Middle East due to regional conflict. The company sunset approximately 30 product lines in the previous year to focus on higher-margin, high-growth platforms like TrueLok Elevate and Fitbone. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick....
Investor releaseQuarter not tagged2026-05-06Orthofix Medical Q1 Earnings Call Highlights
MarketBeat
Orthofix Medical Q1 Earnings Call Highlights
Q1 net sales were $196.4 million (pro forma constant currency +3% excluding discontinued M6 lines) and the company reaffirmed full‑year 2026 guidance of $850–$860 million in net sales with adjusted EBITDA guidance of $95–$98 million and positive free cash flow (ex‑legal settlements). Management reported clear commercial progress in Spine—Global Spine Fixation sales grew ~6% (U.S. +4%), the top 30 distributor partners delivered +27% YoY, distributor transitions are “largely behind us,” and Orthofix is ramping product launches including the 7D FLASH system and the full market launch of Virata in H2 2026. Therapeutic Solutions outperformed the market (Q1 sales $57.8 million, +5% with fracture +6%) and Biologics showed sequential improvement after targeted execution actions, while Limb Reconstruction (Q1 sales $32.8 million) expects to return to double‑digit U.S. growth in H2 2026. Interested in Orthofix Medical Inc.? Here are five stocks we like better. Orthofix Medical (NASDAQ:OFIX) reported first-quarter 2026 results that management said reflect steadier execution, improving stability, and the early benefits of actions taken to reset its Spine commercial channel. Total global net sales for the quarter ended March 31, 2026 were $196.4 million, up 3% year-over-year on a pro forma constant currency basis, excluding discontinued M6 product lines, according to Chief Financial Officer Julie Andrews. President and CEO Massimo Calafiore said the company’s first-quarter performance showed “steady execution, improving stability, and sharper strategic focus,” adding that Orthofix began to see “the expected progress from our Spine commercial channel actions” as the quarter progressed. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook In Spine, Calafiore said global Spine Fixation net sales grew 6% on a constant currency basis, with U.S. net sales growth of 4%. He attributed results to “enhanced commercial focus, deeper procedural penetration, and the ongoing benefits of our distributor transitions,” noting that the distributor transitions are “now largely behind us.” Calafiore also pointed to strong performance among the company’s top distributor partners. “Our top 30 distributor partners delivered net sales growth of 27% year-over-year and 24% on trailing 12 months basis,” he said, describing the results as support for Orthofix’s strategy to prioritize...
Investor releaseQuarter not tagged2026-05-06Orthofix (OFIX) Q1 2026 Earnings Transcript
Motley Fool
Orthofix (OFIX) Q1 2026 Earnings Transcript
Image source: The Motley Fool. Tuesday, May 5, 2026 at 8:30 a.m. ET Chief Executive Officer — Massimo Calafiore Chief Financial Officer — Julie Andrews Senior Vice President, Corporate Communications — Julie Dewey Need a quote from a Motley Fool analyst? Email [email protected] Massimo will start with business performance and operational highlights. Julie Andrews will follow with her financial results and guidance, then we'll open up the call for Q&A. With that, I'll turn the call over to Massimo, who will discuss how our early year execution and recent operational actions are beginning to support improved performance as we move through the year. Massimo? Massimo Calafiore: Thank you, Julie. And good morning, everyone. I appreciate you joining us today. We delivered a good start to 2026. First quarter results reflect steady execution, improving stability and sharper strategic focus. As the quarter progressed, we began seeing the expected progress from our spine commercial channel actions, along with stronger operating discipline, supporting our confidence that performance will continue to build through the year. While these results reflect meaningful progress, they also crystallize where we could further raise the bar. That's why in April, we took deliberate steps to simplify our spine leadership structure, a proactive move as we continue to scale, enabling technologies like 7D and advance the launch of VIRATA later this year. By bringing decision-making closer to the field and increasing accountability through direct oversight, we're improving speed, consistency and commercial focus where it matters the most. Stepping back, Q1 reflects where we are as a company today, moving into the next phase of our journey, executing with greater consistency and strengthening our position to benefit from our innovation pipeline as the year unfolds. What we delivered this quarter supports our confidence in continued improvement. Our priorities are straightforward: execute consistently, convert opportunity into results, and demonstrate progress quarter-by-quarter. Let me turn to business performance highlights, starting with Spine. In Spine, Global Spine Fixation net sales grew 6% on a constant currency basis, with U.S. net sales growth of 4%. Results were supported by enhanced commercial focus, deeper procedural penetration and the ongoing benefits of our distributor transition...
Investor releaseQuarter not tagged2026-05-05Orthofix: Q1 Earnings Snapshot
Associated Press
Orthofix: Q1 Earnings Snapshot
LEWISVILLE, Texas (AP) — LEWISVILLE, Texas (AP) — Orthofix Medical Inc. (OFIX) on Tuesday reported a loss of $20.9 million in its first quarter. On a per-share basis, the Lewisville, Texas-based company said it had a loss of 52 cents. Losses, adjusted for non-recurring costs and stock option expense, came to 12 cents per share. The medical device maker posted revenue of $196.7 million in the period. Its adjusted revenue was $196.4 million. Orthofix expects full-year revenue in the range of $850 million to $860 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OFIX at https://www.zacks.com/ap/OFIX
Investor releaseQuarter not tagged2026-05-05Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
Business Wire
Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
LEWISVILLE, Texas, May 05, 2026--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a constant currency basis, reflecting steady execution during the final stages of distributor transitions, with further improvement expected as productivity increases. Global Spine Fixation1 delivered reported net sales growth of 6% and constant currency growth of 6% compared to the prior year period, including U.S. Spine Fixation growth of 4%, driven by enhanced commercial focus, deeper procedural penetration, and continuing benefits from distributor transition initiatives. Therapeutic Solutions (formerly Bone Growth Therapies) achieved year-over-year net sales growth of 5%, supported by continued demand across the portfolio and effective commercial execution. Global Limb Reconstruction reported net sales growth of 10% and constant currency growth of 3% compared to the prior year period, reflecting continued demand for core fixation and reconstruction systems. First quarter 2026 reported net loss of $(20.9) million and non-GAAP pro forma adjusted EBITDA of $9.7 million, reflecting impacts from geography mix and commercial transitions. "Our first-quarter results reflect steady execution as we complete key spine commercial channel actions and sharpen our strategic focus," said Massimo Calafiore, President and Chief Executive Officer. "While the quarter continued to absorb the impact of these transitions, most notably in biologics, we saw improved commercial focus and operating discipline as the quarter progressed." Mr. Calafiore continued, "Importantly, distributor transitions are now largely behind us, providing greater visibility for the remainder of the year. As we move through 2026, our priorities are cl...
TranscriptFY2026 Q12026-05-05FY2026 Q1 earnings call transcript
Earnings source - 50 paragraphs
FY2026 Q1 earnings call transcript
Welcome to Orthofix's first quarter 2026 earnings call. I'm Julie Dewey, Orthofix's Chief IR and Communications Officer. Joining me today are President and Chief Executive Officer, Massimo Calafiore, and Chief Financial Officer, Julie Andrews. Earlier today, Orthofix released its financial results for the first quarter ended March 31st, 2026. A copy of the press release and supplemental presentation are available on our investor relations website, and a replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially. All statements other than those of historical facts are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements.
Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference various non-GAAP financial measures during today's call. Reconciliations to U.S. GAAP and additional details are in our press release and supplemental materials. Unless otherwise stated, net sales growth rates are on a pro forma constant currency basis and exclude the discounted M6 artificial disc product lines, and all results of operations will be on a non-GAAP as adjusted basis. Here's today's agenda. Massimo will start with business performance and operational highlights. Julie Andrews will follow with our financial results and guidance. We'll open up the call for Q&A.
With that, I'll turn the call over to Massimo, who will discuss how our early year execution and recent operational actions are beginning to support improved performance as we move through the year. Massimo?
Thank you, Julie, and good morning, everyone. I appreciate you joining us today. We delivered a good start to 2026. First quarter results reflect steady execution, improving stability, and sharper strategic focus. As the quarter progressed, we began seeing the expected progress from our Spine commercial channel actions along with stronger operating discipline, supporting our confidence that performance will continue to build through the year. While these results reflect meaningful progress, they also crystallize where we could further raise the bar. That's why in April, we took deliberate steps to simplify our Spine leadership structure, a proactive move as we continue to scale enabling technologies like 7D and advance the launch of Virata later this year. By bringing decision-making closer to the field and increasing accountability through direct oversight, we're improving speed, consistency, and commercial focus where it matters the most.
Stepping back, Q1 reflects where we are as a company today, moving into the next phase of our journey, executing with greater consistency and strengthening our proposition to benefit from our innovation pipeline as the year unfolds. What we delivered this quarter supports our confidence in continued improvement. Our priorities are straightforward: execute consistently, convert opportunity into results, and demonstrate progress quarter by quarter. Let me turn to business performance highlights, starting with Spine. In Spine, global Spine Fixation net sales grew 6% on a constant currency basis with U.S. net sales growth of 4%. Results were supported by enhanced commercial focus, deeper procedural penetration, and the ongoing benefits of our distributor transitions. Importantly, those transitions are now largely behind us. As alignment has improved, we are seeing positive momentum from more consistent field execution.
In Q1, our top 30 distributor partners delivered net sales growth of 27% year-over-year and 24% on trailing 12 months basis, reflecting the success of our strategy to prioritize larger, more dedicated distributors and deeper relationship with our top partners. A key driver of that momentum is 7D, which remains a core differentiator in our surgical ecosystem, enhancing precision, workflow, and surgeon engagement. Following our leadership realignment, we are intensifying our commercial focus on adoption of our 7D FLASH navigation system to deliver a more integrated Spine offering. While Spine is benefiting from better alignment, we are applying the same discipline to Biologics. Performance improved sequentially during the quarter as we implemented targeted actions to strengthen execution, expand account penetration, and increase utilization across the portfolio. We are refining our go-forward strategy, building clinical evidence, and supporting advocacy.
Collectively, these actions are designed to drive improvement through the year and position Biologics to exit 2026 with stronger momentum and a more durable growth profile. Beyond Spine and Biologics, our other growth platforms remained resilient. Our therapeutic solution business, formerly Bone Growth Therapies, delivered 5% year-over-year net sales growth and continue to outperform the broader market. Demands remain stable, utilization is improving, and prescribing activity is increasing across both spine fusion and fracture care. With its consistent performance and healthy margins, this business continues to be an important contributor to margin and cash generation. Global Limb Reconstruction posted 3% constant currency growth, reflecting steady demand across our core fixation and reconstruction systems. Over the past year, we sharpened our focus by prioritizing high-value categories, enhancing our mix with platform like TrueLok Elevate and Fitbone, and de-emphasizing lower return product.
We believe this action position Limb Reconstruction for acceleration as we move through 2026. A common thread across the business is the increasing impact of our innovation pipeline. We will have a full-year contribution from TrueLok Elevate and Fitbone, and we remain on track for the full market launch of Virata in the second half of the year. Together with the continued expansion of our 7D FLASH ecosystem, these platform are designed to deliver differentiated clinical value and support durable multi-year growth. In closing, Q1 was a solid start of the year. We are carrying that momentum forward with disciplined execution and targeted investment. The quality and the commitment of our U.S. Spine distributors is greater than ever and meaningfully contributing to our success. Our innovation pipeline is strong. Our operating model is more focused, and we believe we have the right team and the financial foundation in place.
There is more work to do. We are increasingly confident in our ability to execute, doing fewer things better, sharpening accountability, generating cash, and delivering on what we said we would do. With that, I'll turn the call over to Julie Andrews to review our financial results and guidance.
Thank you, Massimo, and good morning. All growth rates I'll reference today are pro forma constant currency, excluding the impact from discontinued M6 product lines. We delivered a disciplined start to 2026, reflecting an execution that is consistent with our plan. For the first quarter, total global net sales of $196.4 million increased 3% year-over-year. Results reflect steady execution following the Spine commercial channel actions, and we expect further improvement as productivity continues to increase. Spine Fixation was in line with market growth, while Therapeutic Solutions delivered above-market growth, largely offsetting the remaining impact of commercial channel transitions and softness in Biologics. While timing of certain international stocking orders benefited Q1 results by approximately $2 million, the majority of performance reflected underlying execution across our core franchises.
As a reminder, Q1 had one less selling day than last year, which reduced first quarter growth rates by roughly 1.6%. In addition, the CMS team pilot program that began in January and includes bone growth stimulation had a one-time impact of less than 1/2 a percent on our first quarter growth rate, slightly less than the 1% impact we had originally anticipated. Taking these factors into account, our Q1 growth rate was within the range implied by our full-year guidance of 5%-6%. From a segment perspective, global spinal implants, biologics, and enabling technologies delivered $105.8 million in net sales for Q1.
Our performance was supported by continued growth from our top 30 distributors in the U.S., partially offset by the timing of stocking orders from our Middle East distributors due to the impact of the war. Therapeutic Solutions, BGT, net sales were $57.8 million, up 5% as we continued to outperform the market. Fracture sales grew 6% in the quarter. We expect growth to remain above market rates of 2%-3%, driven by disciplined execution, new surgeon additions, and competitive conversions, especially in the fracture channel. Global Limb Reconstruction net sales were $32.8 million in the first quarter, up 3%. U.S. performance was flat, largely due to the timing of OSCAR capital sales. We have recently restructured our capital sales team, which we believe positions us for future growth. Early indicators are encouraging with a strengthening capital pipeline.
Additionally, we are seeing continued acceleration in the worldwide adoption of TrueLok Elevate and Fitbone. As we sharpen our focus on our core Limb Reconstruction pillars and benefit from ongoing portfolio and commercial enhancements, we expect to return to double-digit growth in the U.S. in the second half of 2026. Moving down the P&L, pro forma non-GAAP adjusted growth margin was 70.7%, a 40 basis point improvement over prior year, reflecting the impact of freight and logistics productivity improvements, partially offset by unfavorable geography mix. First quarter pro forma non-GAAP adjusted EBITDA was $9.7 million, in line with our expectations, reflecting impacts from geography mix and commercial transitions. We ended the quarter with $120.9 million in total cash, including restricted cash, providing ample liquidity to support our operating needs and strategic priorities.
The cash increase was a result of financing activities during the quarter, including our draw on the second tranche of our debt facility. As we move through the year, our focus remains on disciplined execution, strengthening our commercial foundation and supporting upcoming product launches that we expect to contribute to growth and margin improvement over time. Let me turn to our full year 2026 guidance. Against the backdrop of our first quarter performance and current visibility, we are reaffirming our full year 2026 guidance. As Massimo noted, we expect performance to improve as we move through the year, driven by a steadier commercial cadence and increasing contributions from recent and planned product launches balanced against macro and operational considerations.
Net sales are expected to range between $850 million and $860 million, representing approximately 5.5% pro forma constant currency growth at the midpoint. Net sales growth is anticipated to be approximately 5% in the first half of the year and about 6% in the second half of the year. These projections are based on current foreign currency exchange rates and do not account for any further changes to exchange rates for the remainder of the year. Non-GAAP adjusted EBITDA is expected to be between $95 million and $98 million, reflecting approximately 70 basis points of margin expansion at the midpoint. Free cash flow is expected to be positive for the full year, excluding potential legal settlements.
In closing, while progress is evident, we are still early in the year and remain focused on converting improved activity levels into consistent above market profitable growth. We remain grounded in operational rigor, disciplined capital deployment and prioritizing high value opportunities across our Spine, Therapeutic Solutions and Limb Reconstruction portfolios with the objective of creating sustainable long-term shareholder value. Let me turn it back to Massimo Calafiore for closing remarks. Massimo?
Thank you, Julie. I am pleased with the progress we made in the first quarter and our anticipated trajectory for the remainder of the year. As we move through 2026, our focus is clear. Deliver quarter by quarter progress, expand margins, generate cash, and translate our innovation and execution into durable shareholder value. Before we open the line for question, I want to thank our global teams and commercial partners for their performance in Q1 and their continued focus and execution as we continue to build Orthofix into the unrivaled partner in MedTech, delivering exceptional experience and life-changing solution. With that, let's go ahead and open the call for your questions.
I would like to remind everyone in order to ask a question and one brief related follow-up, press star, then the one on your telephone keypad. Your first question comes from the line of Tom Stefan with Stifel. Please go ahead.
Great. Hey, guys. Thanks for taking the questions. Nice, nice start to the year. First question on U.S. Spine. Massimo, you talked about the distributor transitions now largely behind you. U.S. Spine up 4%, probably a bit stronger adjusting for selling days. Massimo, maybe talk about how we should think about growth in this business as we move through 2026 and beyond as well would be helpful, and then I'll have a follow-up.
Yeah. As we described, you know, 2026, you're gonna see an acceleration of the business towards the year. I think that we have couple of drivers. You know, all of these, you know, you're gonna see a phase out of the annualization of the distributor termination that we made in order to optimize our distributor infrastructure. A natural acceleration there. Also, as you know, we have a very focused and strong innovation pipeline that is coming. We are on time for the full market launch of the Virata open system and on time on the alpha launch of the Virata MIS. We're gonna see a very good strong contribution of these two foundational system for us in the second half of the year.
The combination between innovation, annualization of the distributor transition and the key capital investment that we're making, I'm very confident they're gonna drive a very strong 2026. As you know, we made, we shorten, let's say, the distance between myself and the business. I think that the optimization on the leadership side is let me be very close to the field, very be present and keep nurturing the talent that we have. I'm very excited about where we are with Spine. You know, we made bold decision to create a strong foundation, and now it's on us to execute.
Got it. That's great. Super helpful, Massimo. My follow-up just on sort of guidance and cadence for rest of the year. Julie, this may be for you. Reaffirming 1H constant currency growth of 5%, you did 3% in 1Q. I guess, A, do we think about 2Q as around 7% constant currency? I just want to make sure, you know, I'm contextualizing the 5% correctly for 1H. A, is that correct? B, for 2H, any comments on selling day dynamics, maybe other fundamental considerations sort of from a headwind perspective in the back half that we should be mindful of for top line? Thanks.
Yeah. Tom, we are reaffirming our guidance. You know, our comments were we do expect growth in the first half of the year to be around the 5% and then accelerating into 6% in the second half of the year. If you look at Q1, when you adjust it for the selling day, one less selling day and the team's impact, we were right at kind of that 5% growth rate in Q1. In Q2, we would expect to be our growth rate, yeah, I think to be in the 6%, 6% range, would get you there for Q2.
Great. Thank you.
Your next question comes from the line of Caitlin Roberts with Canaccord Genuity. Please go ahead.
Hi. Thanks so much for taking the questions. Maybe just a little bit more color on the geopolitical impact in the Q1, and then just any expectations that might be built into the guidance there.
Hi, Caitlin. You know, built into our guidance, we expect very minimal impact for the full year, related to the activities in the Middle East. Q1, there was a little bit of what we see as timing just in our Spine business, primarily with orders, but kind of more than made up for with other stocking orders. Very limited impact that we have from that and not necessarily in our guidance for the year.
Understood. Maybe just talk a little bit about putting the Biologics business under the Limb Recon leadership and where you expect Biologics growth to end 2026.
For Biologics, I think that we are expecting to go back to market growth. It's clear that we have still work to do, but, you know, since the realignment, the performance are improved sequentially during the quarter. The targeted action that we are putting in place are working. You know, we are strengthening the execution, we expand account penetration, and also we increase the utilization of the portfolio, as you hinted before, not just the Spine, but also in the orthopedic side. I'm very confident about the quality of our biological portfolio. I think that the optimization that we're putting forward in terms of sales channel and leadership is working. Let me highlight a specific comment that you made.
It's not the realignment under orthopedics, it's more a realignment under a leader that is Patrick Fisher, who has a lot of experience in the space. Of course, as said before, you're gonna see a natural expansion in the orthopedic side, but the idea of the realignment was mostly driven by the talent and the experience that we have in the company around this specific space.
Great. Thanks so much.
Your next question comes from the line of Matthew Blackman with TD Cowen. Please go ahead.
Good morning, everybody. Can you hear me okay?
Yeah. Thank you. Good morning, Matt.
Good morning. Two little housekeeping questions for Julie, and then one question for Massimo. I mean, Julie, you didn't call it out, so I'm assuming it wasn't a headwind, but any impact from weather in the quarter, and also there was a big hospital strike on the West Coast. Just any other headwinds to call out besides the ones you did mention already. Can you give us just a sense of the size of the Biologics business, even the roughest sense, whether it's as a percent of the total business or a percent of Spine, just for some context there. A follow-up for Massimo.
Okay. Matt, no, we didn't see, you know, any sustained impact from the weather, and we didn't have an impact from the hospital strike on the West Coast. Those did not impact our business. From a Biologics perspective, we don't break that out separately. I can't give you context in terms of the size. I think, you know, I'd point you to a couple of places. You can look at pre-merger results. A portion of our Biologics revenue, you can see in our Q with our MTF service fee.
Okay
A portion.
I remember that. Yes. Massimo, as you sort of look at the top 30 distributors, obviously tremendous performance there. Is there anything that you can take from that playbook and port over to the rest of the distributor book, such that you can sort of bring along that part, that rest of the business? I mean, obviously not, you know, sort of approaching 30% growth, but anything that you can do to sort of bring up the tail of the business, now that you're seeing, you know, obviously really solid execution on a large part of the business there. Just curious how you can execute across the entire distributor network now.
Yeah. Thank you, Matt, for the question. Yeah, the plan that we put in place was divided different phases. Phase number 1 is the one that we just accomplished. Phase number 2 is really start to pick among the network that we have. The next year of distributor that we wanna help to grow. As you hinted, we're gonna apply the same discipline and rigor that we apply for our top 30 distributor to the second tier to make sure that over time, they can grow and they create the operational excellence we are expecting by our partner. 2026 is gonna be mostly for us working on the, you know, on the next 30, more than keep fueling the growth with our top 30 and laser focus on the second tier.
Got it. Thank you so much.
Again, if you would like to ask a question, press star one on your telephone keypad. Your next question comes from the line of Mike Petusky with Barrington Research. Please go ahead.
Hey, good morning. Juggling a couple of conference calls. I may have missed this. Did you guys give any detail around 7D placements, you know, any percentages or just any detail around that this morning?
Hi, Mike. We're doing that more on a biannual or annual basis, updating those. Our last update on those were in our Q4 call. As a reminder, for 2025, our Voyager earn-out placements increased 30%, and the accounts exceeded their purchase commitments by more than 50%.
Okay. Okay. Then I guess I just wanna ask around U.S. Ortho or Limb Reconstruction. It feels like the momentum has slowed there last couple of quarters, and I just can you guys speak to that and maybe speak to actions that you may be taking to try to re-accelerate growth there? Thanks.
Hi, Mike. You know, the momentum hasn't slowed. We've had some transient issues, or things that we're dealing with. We did sunset about 30 product lines last year. We really saw that start to impact in Q4. It continues, you know, some into Q1 as well. Really the timing of OSCAR sales, which is a capital sale, in Q1 impacted the overall growth rate. Very good results and adoption that we're seeing on Elevate and Fitbone. We're, again, we expect that business to return in the U.S. to double-digit growth in the back half of 2026.
Okay. Very good. Thank you.
There are no further questions at this time. I will now turn the call back over to Julie Dewey for closing remarks.
Thank you for your questions and for joining us today. We appreciate your time and interest in Orthofix. If you need any additional information, please reach out. We look forward to updating you next quarter. This concludes today's call.
Ladies and gentlemen, thank you all for joining. You may now disconnect.
Investor releaseQuarter not tagged2026-04-21Orthofix to Report First Quarter 2026 Financial Results
Business Wire
Orthofix to Report First Quarter 2026 Financial Results
Company to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time LEWISVILLE, Texas, April 21, 2026--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the "Investors" section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix. About Orthofix Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company delivers technology-enabled solutions that support improved clinical outcomes and more efficient care across the continuum. Orthofix offers a focused and differentiated portfolio spanning spinal implants, bone growth therapies, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Learn more at Orthofix.com and follow Orthofix on LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20260421478333/en/ Contacts Investors and Media Julie Dewey, IRC Chief Investor Relations & Communications Officer [email protected] +1 209.613.6945
Investor releaseQuarter not tagged2026-03-02Orthofix Medical Inc. (OFIX) Target Reduced at Canaccord Following Q4 Results and 2026 Outlook Update
Insider Monkey
Orthofix Medical Inc. (OFIX) Target Reduced at Canaccord Following Q4 Results and 2026 Outlook Update
Orthofix Medical Inc. (NASDAQ:OFIX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Orthofix Medical Inc. (NASDAQ:OFIX) is given the tenth position on our list of small-cap stocks. TheFly reported on February 26 that Canaccord reduced its price target for OFIX from $24 to $20 and gave it a Buy rating. The modification comes after the company updated its financial model to reflect the fourth-quarter performance and its outlook for 2026. On February 24, Orthofix Medical Inc. (NASDAQ:OFIX) published its 2026 outlook. The company projects adjusted EBITDA to be between $95 million and $98 million, and it expects positive free cash flow for the whole year. This does not include any potential outcomes of a court settlement. The management has said that increasing commercial execution, increasing market penetration, and promoting broader use of enabling technologies such as 7D FLASH Navigation are priorities for 2026. The company expects full-year revenue contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails, in addition to the scheduled full launch of VIRATA in the second part of the year. Simplifying the Spine commercial channel, expanding the Biologics offering, and maintaining development throughout Limb Reconstruction and BGT operations are other areas of concentration. According to the leadership, these programs should assist in maintaining consistent revenue growth, enhancing margins, and boosting cash flow in 2026. Orthofix Medical Inc. (NASDAQ:OFIX) is a global medical device company focused on spine and orthopedic solutions. It develops and markets implants, biologics, and bone growth therapies to support musculoskeletal healing and improve patient mobility and recovery outcomes. While we acknowledge the potential of OFIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts. Disclosure: None. Follow Insider Monkey on Google News.
Investor releaseQuarter not tagged2026-02-26Brookdale Stock Up 200%, but One Fund Dumped Its $6.5 Million Stake Last Quarter
Motley Fool
Brookdale Stock Up 200%, but One Fund Dumped Its $6.5 Million Stake Last Quarter
On February 17, 2026, AYAL Capital Advisors Ltd reported selling out of Brookdale Senior Living (NYSE:BKD) in the fourth quarter. According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, AYAL Capital Advisors sold its entire position of 762,100 shares in Brookdale Senior Living (NYSE:BKD). The fund’s quarter-end position in the company dropped by $6.45 million, reflecting the combined impact of the exit. This was a full exit. Top holdings after the filing: NYSE:NVRI: $15.05 million (8.2% of AUM) NYSE:SEI: $14.21 million (7.8% of AUM) NASDAQ:OFIX: $11.25 million (6.2% of AUM) NYSE:BGSI: $9.26 million (5.1% of AUM) NYSE:PAR: $7.44 million (4.1% of AUM) As of February 17, 2026, shares were priced at $16.64, up 200% over the past year. Brookdale Senior Living operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities (CCRCs) The firm generates revenue primarily through resident fees for housing, care services, and ancillary offerings within its owned, leased, and managed communities It serves middle to upper-income seniors seeking residential and healthcare support, with a focus on aging populations requiring varying levels of daily assistance and memory care Brookdale Senior Living is a leading provider of senior housing and care services in the U.S., managing a broad portfolio of communities tailored to diverse senior needs. The company leverages a multi-segment model to address independent living, assisted living, memory care, and skilled nursing, positioning itself to benefit from demographic trends and increasing demand for senior care. Its scale and operational expertise provide a competitive edge in a fragmented industry, enabling efficient service delivery and broad market reach. When a stock triples in a year, disciplined managers face a simple question: lock in gains or lean in further. This exit suggests the former. Brookdale just posted a year of tangible operational progress. Full-year 2025 revenue rose to $3.04 billion, RevPAR climbed 5.7%, and adjusted EBITDA jumped 18.5% to $457.8 million. Meanwhile, ccupancy trends improved meaningfully, with fourth-quarter weighted average occupancy up 310 basis points year over year. Even with that momentum, however, Brookdale still posted a $263 million net loss for 2025 and c...
Investor releaseQuarter not tagged2026-02-25Orthofix Medical Inc (OFIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
GuruFocus.com
Orthofix Medical Inc (OFIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
This article first appeared on GuruFocus. Total Global Net Sales: $218.6 million in Q4, a 3% increase. Global Spinal Implants, Biologics, and Enabling Technologies Sales: $112.3 million in Q4. Bone Growth Therapies (BGT) Net Sales: $68.3 million, up 7%. Global Limb Reconstruction Sales: $38 million in Q4, driven by 8% US growth. Adjusted Gross Margin: 71.4% in Q4. Adjusted EBITDA: $29.2 million in Q4, or 13.4% of net sales, with a margin expansion of approximately 230 basis points. Free Cash Flow: $16.8 million in Q4; full year free cash flow, excluding restructuring charges, was $3.1 million. Total Cash: $85.1 million, including restricted cash. 2026 Full Year Net Sales Guidance: $850 million to $860 million. 2026 Full Year Adjusted EBITDA Guidance: $95 million to $98 million. Expected Adjusted Gross Margin for 2026: Approximately 72.5%. Expected Capital Expenditures for 2026: $45 million to $50 million. Warning! GuruFocus has detected 6 Warning Signs with OFIX. Is OFIX fairly valued? Test your thesis with our free DCF calculator. Release Date: February 24, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Orthofix Medical Inc (NASDAQ:OFIX) achieved its 8th consecutive quarter of adjusted EBITDA growth, highlighting consistent financial performance. The company reported strong net sales growth in its global spine fixation business, with a 10% increase in Q4 and for the year. The 7D flash navigation system saw a 30% increase in placements in 2025, with earnout customers exceeding purchase commitments by over 50%. Orthofix Medical Inc (NASDAQ:OFIX) successfully launched several new products, including TrueLok Elevate and FITBONE, contributing to an 8% growth in US limb reconstruction in Q4. The company generated robust free cash flow of $16.8 million in Q4, demonstrating strong operational discipline and scalability. The distributor transition in 2025 created temporary pressure on performance, although improvements were noted by the end of Q4. There was softness in the biologics segment, partially due to a strategic shift from capital sales to the Voyager earnout program. The company is recalibrating its 3-year financial targets, extending the timeline by one year to fully capture expected benefits from spine commercial channel optimization. Orthofix Medical Inc (NASDAQ:OFIX) faces a potential legal sett...
Investor releaseQuarter not tagged2026-02-25Orthofix Medical Inc. Q4 2025 Earnings Call Summary
Moby
Orthofix Medical Inc. Q4 2025 Earnings Call Summary
Performance was anchored by strong results in Bone Growth Therapies (BGT) and U.S. Limb Reconstruction, alongside double-digit growth in Global Spine Fixation. Management successfully transitioned the Spine commercial channel, with the top 30 U.S. distributor partners now driving over 75% of net sales compared to less than 50% in early 2024. The 7D FLASH navigation system continues to serve as a key differentiator, with earnout customers exceeding purchase commitments by more than 50%, validating the shift from capital sales to utilization-based models. Limb Reconstruction was rebranded to focus on four high-value clinical categories, representing a $2.6 billion market opportunity where management sees limited competition. BGT growth reached 7% in Q4, more than double the market rate, driven by increased utilization and procedural cross-selling in spine fusion and fracture management. Management recalibrated the three-year financial target timeline by one year to 2028 to fully capture the operational leverage and growth benefits from the deliberate Spine channel transformation. The full market release of the VIRATA Spinal Fixation System in the second half of 2026 is expected to be a multi-year growth catalyst for the U.S. Spine business. Management anticipates 2026 net sales between $850 million and $860 million, implying approximately 5.5% pro forma constant currency growth at the midpoint. Adjusted EBITDA is projected to reach $95 million to $98 million, with margin expansion weighted toward the second half of the year due to R&D investment timing. The refreshed 2028 long-range plan targets a 6.5% to 7.5% net sales CAGR and mid-teens adjusted EBITDA margins, supported by 300 basis points of gross margin improvement. Positive free cash flow is expected for the full year 2026, though management noted this excludes the impact of potential legal settlements and will not be positive in every quarter. The discontinuation of the M6 artificial disc product line impacted reported results but allowed for sharpened focus on core growth pillars. A CMS pilot program (TEAM) starting in January 2026 is expected to create a one-time 1% headwind to BGT revenue in the first quarter. Management flagged a $1 million to $2 million anticipated impact from tariffs in 2026, which is factored into the current guidance. A legal settlement accrual was taken in Q3 2025; while the ti...
Investor releaseQuarter not tagged2026-02-25Orthofix Medical Q4 Earnings Call Highlights
MarketBeat
Orthofix Medical Q4 Earnings Call Highlights
Q4 financials: Orthofix reported pro forma Q4 net sales of $218.6M (up ~3% cc), pro forma non‑GAAP adjusted EBITDA of $29.2M (13.4%) — its eighth consecutive quarter of adjusted EBITDA growth — and a pro forma gross margin of 71.4%, with Q4 free cash flow of $16.8M and total cash of $85.1M. Operational momentum and product pipeline: Bone Growth Therapies grew 7% to $68.3M and U.S. Limb Reconstruction rose (Q4 net sales $38.0M, U.S. +8%), while spine channel optimization boosted the top 30 U.S. distributors to >75% of U.S. sales and ~25% YoY growth. Management also expects full market launches of the VIRATA systems in the second half of 2026. 2026 guidance and longer-term targets: Orthofix guided 2026 net sales of $850–860M (midpoint ~+5.5% pro forma cc), non‑GAAP adjusted EBITDA of $95–98M, and positive free cash flow, and refreshed its 2026–2028 targets to a 6.5–7.5% net sales CAGR with mid‑teens EBITDA margin by 2028. Interested in Orthofix Medical Inc.? Here are five stocks we like better. Orthofix Medical (NASDAQ:OFIX) reported fourth-quarter 2025 results that management said capped a year of “meaningful operational progress,” highlighted by continued momentum in Bone Growth Therapies and U.S. Limb Reconstruction, improving performance in global spine fixation, and the company’s eighth consecutive quarter of adjusted EBITDA growth. Chief Executive Officer Massimo Calafiore said Orthofix delivered “strong, consistent performance” in Bone Growth Therapies (BGT) and U.S. Limb Reconstruction, while efforts to finalize its spine commercial channel supported double-digit net sales growth in global spine fixation. Calafiore noted distributor transitions implemented earlier in 2025 created “temporary pressure” in the quarter, but said performance improved meaningfully exiting Q4 and that the transition is now largely behind the company. → Hinge Health’s AI Moat Might Be Its Patient Movement Data Chief Financial Officer Julie Andrews said total global net sales for Q4 were $218.6 million, up 3% on a pro forma, constant-currency basis excluding the discontinued M6 artificial disc product lines. She attributed growth to strength in BGT and U.S. limb reconstruction. Global spinal implants, biologics, and enabling technologies: Q4 net sales of $112.3 million. Andrews said results were supported by targeted distributor transitions in key geographies, partially offset...